title: Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN).
abstract: Complex Regional Pain Syndrome (CRPS) is a neuropathic pain syndrome, which involves glial activation and central sensitization in the central nervous system. Here, we describe positive outcomes of two CRPS patients, after they were treated with low-dose naltrexone (a glial attenuator), in combination with other CRPS therapies. Prominent CRPS symptoms remitted in these two patients, including dystonic spasms and fixed dystonia (respectively), following treatment with low-dose naltrexone (LDN). LDN, which is known to antagonize the Toll-like Receptor 4 pathway and attenuate activated microglia, was utilized in these patients after conventional CRPS pharmacotherapy failed to suppress their recalcitrant CRPS symptoms.
authors.affiliation: Department of Medicine, Alpert Medical School of Brown University, 102 Smithfield Ave, Pawtucket, RI 02860, USA. painri@yahoo.com
authors.forename: Pradeep
authors.initials: P
authors.lastname: Chopra
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cooper
mesh_terms: D002648:Child; D020918:Complex Regional Pain Syndromes / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage*; D010147:Pain Measurement / Q000379:methods; D016896:Treatment Outcome
chemical_list: D009271:Naltrexone
references.citation: J Neuroimmune Pharmacol. 2013 Jun;8(3):564-75
references.pmid: 23054370
references.citation: Clin J Pain. 2009 May;25(4):273-80
references.pmid: 19590474
references.citation: Eur J Pain. 2012 Feb;16(2):182-95
references.pmid: 22323371
references.citation: Neurochem Res. 2011 Jan;36(1):1-6
references.pmid: 20820913
references.citation: Drug Alcohol Depend. 2004 Jul 15;75(1):79-88
references.pmid: 15225891
references.citation: Pain. 2012 May;153(5):1063-1073
references.pmid: 22424691
references.citation: Brain Behav Immun. 2009 Jan;23(1):85-91
references.pmid: 18786633
references.citation: Acta Neurol Scand. 2000 Apr;101(4):262-9
references.pmid: 10770524
references.citation: Pain. 1997 Aug;72(1-2):277-82
references.pmid: 9272813
references.citation: J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):892-8
references.pmid: 21493756
references.citation: Ann Neurol. 2012 Oct;72(4):536-49
references.pmid: 23109148
references.citation: J Neuroimmune Pharmacol. 2013 Jun;8(3):547-63
references.pmid: 23188523
references.citation: Neurol Clin. 1995 May;13(2):351-63
references.pmid: 7643830
references.citation: Nat Clin Pract Neurol. 2007 May;3(5):291-6
references.pmid: 17479076
references.citation: J Neuroimmune Pharmacol. 2013 Jun;8(3):452-69
references.pmid: 22923151
references.citation: J Pharmacol Exp Ther. 2000 May;293(2):607-17
references.pmid: 10773035
references.citation: Neurology. 2011 Aug 2;77(5):496-502
references.pmid: 21810699
references.citation: Pain Med. 2010 Aug;11(8):1274-7
references.pmid: 20704676
references.citation: Neurology. 2004 Aug 24;63(4):693-701
references.pmid: 15326245
references.citation: Arch Dis Child. 2004 Jul;89(7):611-4
references.pmid: 15210488
references.citation: Neuron. 2012 Feb 23;73(4):638-52
references.pmid: 22365541
references.citation: Pain Med. 2009 May-Jun;10(4):663-72
references.pmid: 19453963
references.citation: Nature. 2005 Dec 15;438(7070):1017-21
references.pmid: 16355225
references.citation: Expert Opin Pharmacother. 2009 Dec;10(17):2897-904
references.pmid: 19929708
references.citation: Neurology. 2003 Dec 23;61(12):1707-15
references.pmid: 14694034
references.citation: N Engl J Med. 2000 Aug 31;343(9):625-30
references.pmid: 10965009
references.citation: Neurology. 2003 Aug 26;61(4):515-9
references.pmid: 12939426
references.citation: Glia. 2013 Mar;61(3):349-60
references.pmid: 23108585
references.citation: Trends Pharmacol Sci. 2009 Nov;30(11):581-91
references.pmid: 19762094
references.citation: Pain. 2009 May;143(1-2):3-4
references.pmid: 19232829
references.citation: Infection. 2002 Dec;30(6):396-9
references.pmid: 12478332
references.citation: Dev Med Child Neurol. 2006 Jun;48(6):526-8
references.pmid: 16700948
references.citation: Ann Neurol. 2009 Jun;65(6):629-38
references.pmid: 19557864
references.citation: J Neural Transm (Vienna). 2011 Sep;118(9):1301-9
references.pmid: 21331457
references.citation: Pain Physician. 2011 Sep-Oct;14(5):419-24
references.pmid: 21927045
references.citation: J Stud Alcohol Drugs. 2012 Nov;73(6):991-7
references.pmid: 23036218
references.citation: Pain Physician. 2011 May-Jun;14(3):311-6
references.pmid: 21587336
references.citation: Nat Rev Neurosci. 2009 Jan;10(1):23-36
references.pmid: 19096368
references.citation: J Neuroinflammation. 2012 Oct 03;9:230
references.pmid: 23034047
references.citation: Mov Disord. 2007 May 15;22(7):1017-20
references.pmid: 17415799
references.citation: Neurology. 2001 Jun 26;56(12):1762-5
references.pmid: 11425951
references.citation: Pain. 2011 Jul;152(7):1453-1454
references.pmid: 21458161
references.citation: J Neuroimmune Pharmacol. 2013 Jun;8(3):477-88
references.pmid: 22588663
references.citation: Pain. 2011 Dec;152(12):2690-2700
references.pmid: 21816540
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5856-61
references.pmid: 15809417
references.citation: Eur J Neurosci. 2008 Jul;28(1):20-9
references.pmid: 18662331
references.citation: Pain Med. 2011 May;12(5):842-3
references.pmid: 21463465
references.citation: Muscle Nerve. 2000 Feb;23(2):198-205
references.pmid: 10639611
references.citation: Dev Med Child Neurol. 2009 Sep;51(9):759-61
references.pmid: 19583739
references.citation: Mol Brain. 2012 May 20;5:16
references.pmid: 22607655
references.citation: Lancet Neurol. 2011 Jul;10(7):637-48
references.pmid: 21683929
references.citation: J Affect Disord. 2012 Mar;137(1-3):151-5
references.pmid: 22252095
references.citation: Exp Brain Res. 2003 Jul;151(1):1-8
references.pmid: 12743675